A recent Danish study concluded that half of people stop taking the Ozambek to lose weight within a year of its use, which causes fears of the ability of its users to bear its side effects or its material cost.
The new category of anti-obese drugs, which is the Betkid-1 Bittagon-1 GLP-1RS, has been noticeable in helping individuals to lose weight.
However, a new study presented at the annual meeting of this year of the European Association for the Study of Diabetes “EASD”, in Vienna (15-19 September)-was written by the Yorik Alert website-that half of non-adults with diabetes who start taking Simajlotide to lose weight in Denmark stop treatment within a year.
“This decrease is worrying, because these drugs are not a temporary and fast solution. In order for these drugs to work effectively, they must be taken in the long term. All their useful effects in controlling appetite are lost when stopping taking the medicine,” said the main researcher, Professor Remar W. Tomsen, of the Clinical Epidemiology Department at the University of Arheus Hospital in Denmark.
The GLP-1RA, which originally developed for diabetes, showed promising results in enhancing weight loss by reducing appetite and increasing satiety signs from the intestine to the brain.
However, the “GLB -1RA” inhibitors are expensive, and health differences have exacerbated, as obesity is not proportional to marginalized ethnic, social and economic societies. Moreover, weight restoring is common after stopping taking the medicine, indicating that people may need to continue taking these medications to maintain their weight.
However, there are increasing concerns that many people may stop taking obesity medications shortly after starting them, but population data is still rare.
To provide more evidence, the researchers used data from national health records to study the possibility and reasons for stopping the use of Simajlotide to lose weight in all adults (18 years and over) who are not diabetes who have started treatment between the date of the launch of the drug in Denmark (December 1, 2022) and October 1, 2023.
Of the 77 thousand and 310 users for the first time for the drug Simajlotide to lose weight, more than half of them (40 thousand and 262 people, with an average age of 50 years, 72% of whom are women) who stopped taking it after one year, with a stop of 18%, 31% and 42% from treatment during 3, 6 and 9 months, respectively.
Why does this large number of people stop using the drug?
Excessive costs
The study concluded that the most common factor affecting the possibility of stopping treatment is age, as the possibility of the younger users – who are between the ages of 18 and 29 years than treatment during the first year – was 48% higher compared to those between the ages of 45 and 59, after controlling the gender differences. Likewise, the possibility of stopping users in low -income areas during the first year was 14% higher compared to those living in high -income areas.
Both workers highlight the potential effect of the costs of these medications (about 2340 dollars annually) for the lowest dose of Simajlotide as of June 2025, which represents a major obstacle to treatment for many people.
Side effects
In addition, people who had previously used the digestive system drugs – which might indicate that they were more likely to the common digestive side effects reported by the “GLB -1RA” users such as nausea, vomiting and diarrhea – were 9% more likely to stop using Simajlotide during the first year.
Likewise, people with a history of using psychiatric drugs were 12% more likely to stop treatment during the first year, while those suffering from cardiovascular disease or other chronic cases were 10% more likely to stop treatment early, which also indicates a high probability of exposure to side effects.
“This is particularly concerned that people with obese -related diseases may benefit more than treatment,” said Professor Thompson by saying.
The study found that males were 12% more likely to stop treatment within one year of females, which may reflect a non -weight loss of weight due to the results of the best weight loss that were generally noticed in females who take the GLP -1 RAS compared to males.
“These results are new and shed light on the reasons for high early stopping rates from using Simajlotide to lose weight in a realistic environment,” Thomson said. “With the suffering of more than half of the adults in Europe from weight gain or obesity, those who may benefit more than interventions that encourage commitment are essential to improving the use of treatment, subsequent health results and quality of life.”